GammaCan to Present and Webcast at Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference

  
    
  
  
    
      GammaCan International, Inc. ("GammaCan" or "the Company") (OTCBB:GCAN), 
      a developer of immunotherapies for the treatment of cancer, today 
      announced that Patrick Schnegelsberg, Chief Executive Officer, is 
      scheduled to present VitiGam™, GammaCan's lead 
      product under development for the treatment of Stage III and Stage IV 
      melanoma at the Acumen BioFin Rodman & Renshaw 4th Annual Global 
      Healthcare Conference. GammaCan’s presentation 
      is scheduled for Monday, May 14th at 2:55 PM CST 
      (8:55 AM EDT).
    
    
      Interested parties may access a live audio webcast of the presentation 
      via the investor information section of the GammaCan website, www.GammaCan.com. 
      A replay of the presentation will be archived on the site for 30 days 
      following the presentation.
    
    
      About GammaCan
    
    
      GammaCan develops innovative immunotherapy and related approaches to 
      treat cancer. GammaCan's platform technology is based on IgGs, a safe, 
      relatively non-toxic human plasma-based product used to treat a variety 
      of immune deficiencies and autoimmune diseases. In cancer, IgG-based 
      therapies work by strengthening the patient's immune system. Many 
      experts currently view immunotherapy as a future alternative to 
      chemotherapy. For more information about GammaCan, visit www.GammaCan.com.
    
    
      About VitiGam™
    
    
      VitiGam™ is a first-in-class IgG-based 
      anti-cancer immunotherapy being developed for the treatment of Stage III 
      and Stage IV melanoma. GammaCan is planning to submit its 
      Investigational New Drug Application (IND) for VitiGam™ 
      to the FDA in the near future. The Company is expecting to commence 
      human clinical trials shortly thereafter. VitiGam™ 
      is an IgG-based product manufactured from the plasma of donors with 
      Vitiligo, a benign skin condition affecting up to 2% of the general 
      population. Studies have shown that this "enriched" IgG formulation 
      contains potent anti-melanoma activity. Based on these studies, GammaCan 
      expects VitiGam™ to provide both, specific 
      anti-melanoma activity (directed against melanoma cells), and 
      non-specific anti-cancer activity.
    
    
      About Metastatic Melanoma
    
    
      Melanoma is a deadly form of skin cancer. According to the American 
      Cancer Society, melanoma accounts for approximately 4% of all skin 
      cancers but causes about 75% of all skin cancer-related deaths. An 
      estimated 60,000 people will be diagnosed and nearly 8,000 people will 
      die from melanoma in 2007 in the U.S. alone. If rapidly diagnosed and 
      surgically removed, early-stage melanoma is usually curable. However, 
      for patients with metastatic melanoma, the prognosis is poor resulting 
      from limited treatment alternatives, and a median survival time of 8.5 
      months and a 5-year survival rate of 3%. There has been little change in 
      these results in excess of 25 years. The incidence of melanoma has 
      increased more rapidly than any other cancer during the past 10 years. 
      The last drug to treat patients with melanoma was approved by the FDA 30 
      years ago.
    
    
      Safe Harbor Statement
    
    
      Statements in this document that are not purely historical are 
      forward-looking statements. Forward-looking statements in this release 
      include statements regarding: the commercialization of anti-cancer 
      immunotherapies and the Company's efforts to develop therapies to boost 
      the immune systems of cancer patients by the use of IgG-based therapy. 
      Actual outcomes and the Company's actual results could differ materially 
      from those in such forward-looking statements. Factors that could cause 
      actual results to differ materially include risks and uncertainties such 
      as the inability to finance the planned development of the technology, 
      the inability to hire appropriate staff to develop the technology, 
      unforeseen technical difficulties in developing the technology, the 
      inability to obtain regulatory approval for human use, competitors' 
      therapies proving to be more effective, cheaper or otherwise preferable 
      for consumers, the inability to market the product we produce, all of 
      which could, among other things, delay or prevent product release, as 
      well as other factors expressed from time to time in GammaCan's periodic 
      filings with the Securities and Exchange Commission (the "SEC"). As a 
      result, this press release should be read in conjunction with GammaCan's 
      periodic filings with the SEC, which are incorporated herein by 
      reference. The forward-looking statements contained herein are made only 
      as of the date of this press release, and GammaCan undertakes no 
      obligation to publicly update such forward-looking statements to reflect 
      subsequent events or circumstances.